Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma

Fig. 6

Validation of influence tumor immune therapy and tumor Mutation Burden exert using the m6A-related lncRNA model in TCGA sets. (A) A heat map indicating expression of immune molecules in the high- and the low-risk groups. (B) GO enrichment analysis. (C) TIDE differences between the high- and the low-risk groups. (D and E) Waterfall plot showing different mutation frequencies in the high-risk groups (D) and the low-risk groups (E). (F) TMB differences in the high- and the low-risk groups. (G) Kaplan-Meier curve analysis indicates relationship between prognosis of patients with PDAC and TMB level. (H) Outcome of patients with different TMB level influenced by risk scores

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us